

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th colspan="2" style="text-align: left; padding: 2px;">Complete if Known</th> </tr> <tr> <td style="width: 40%; padding: 2px;">Application Number</td> <td style="padding: 2px;">10/815,262</td> </tr> <tr> <td style="padding: 2px;">Filing Date</td> <td style="padding: 2px;">March 31, 2004</td> </tr> <tr> <td style="padding: 2px;">First Named Inventor</td> <td style="padding: 2px;">John F. Engelhardt</td> </tr> <tr> <td style="padding: 2px;">Group Art Unit</td> <td style="padding: 2px;">1633</td> </tr> <tr> <td style="padding: 2px;">Examiner Name</td> <td style="padding: 2px;">Kevin Hill</td> </tr> </table>	Complete if Known		Application Number	10/815,262	Filing Date	March 31, 2004	First Named Inventor	John F. Engelhardt	Group Art Unit	1633	Examiner Name	Kevin Hill
Complete if Known													
Application Number	10/815,262												
Filing Date	March 31, 2004												
First Named Inventor	John F. Engelhardt												
Group Art Unit	1633												
Examiner Name	Kevin Hill												
Sheet 1 of 2	Attorney Docket No: 875.074US1												

US PATENT DOCUMENTS				
Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate
	US-20080206198A1	08/28/2008	Engelhardt, J. F, et al.	08/07/2007
	US-20080213221A1	09/04/2008	Engelhardt, J. F, et al.	08/07/2007

FOREIGN PATENT DOCUMENTS				
Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T ¹

OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ¹
	Application Serial No. 09/689,136 (Atty Ref 875.032US1), Response filed 04-11-02 to Restriction requirement mailed 10-11-01, 12 pgs		
	Application Serial No. 09/689,136 (Atty Ref 875.032US1), Restriction requirement mailed 10-11-01, 9 pgs		
	Application Serial No. 10/815,557 (Atty Ref 875.085US1), Amendment and Response mailed 5-14-08 to Final Office Action mailed 11-14-07, 18 pages		
	Application Serial No. 10/815,557 (Atty Ref 875.085US1), Non-Final Office Action mailed 08/13/2008, 25 pgs		
	Application Serial No. 11/890,761 (Atty Ref 875.074US2), Preliminary Amendment mailed 5-19-08, 8 pgs.		

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	<i>Complete if Known</i>	
	Application Number	10/815,262
	Filing Date	March 31, 2004
	First Named Inventor	John F. Engelhardt
	Group Art Unit	1633
	Examiner Name	Kevin Hill
Sheet 2 of 2	Attorney Docket No: 875.074US1	

OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	DJALDETTI, M., et al., "SEM observations on the effect of anthracycline drugs on cultured newborn rat cardiomyocytes (ABSTRACT ONLY)", <i>Basic Res Cardiol</i> , Vol. 6, (1988), 627-627	
	GROSS, R., "Clinical problems of optimum bioavailability, in particular in cytostatic therapy (ABSTRACT ONLY)", <i>Arzneimittelforschung</i> , Vol. 26(1A), (1976), 130-135	
	PATEL, et al., "Identification of Yeast DNA Topoisomerase II Mutants Resistant to the Antitumor Drug Doxorubicin: Implications for the Mechanisms of Doxorubicin Action and Cytotoxicity", <i>Pharmacol. 52(4)</i> , (1997), 658-666	

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant is to place a check mark here if English language Translation is attached